Literature DB >> 16384749

Determination of succinylacetone in dried blood spots and liquid urine as a dansylhydrazone by liquid chromatography tandem mass spectrometry.

Osama Y Al-Dirbashi1, Mohamed S Rashed, Herman J Ten Brink, Cornelis Jakobs, Najlaa Filimban, Lujane Y Al-Ahaidib, Minnie Jacob, Moeen M Al-Sayed, Zuhair Al-Hassnan, Eissa Faqeih.   

Abstract

Succinylacetone (SA) is a specific marker for the inherited metabolic disease, hepatorenal tyrosinemia. We developed a stable-isotope dilution liquid chromatography tandem mass spectrometry for the determination of SA in dried blood spots (DBS) and liquid urine using a (13)C(4)-SA as internal standard. SA was extracted, converted to the butyl ester and derivatized with dansylhydrazine (Dns-H). Calibration curves in DBS and urine calibrators were linear up to 100 and 30 microM, respectively. At a signal-to-noise ratio of 3, the limits of detection in DBS and urine were 0.2 and 0.005 microM, respectively. Total run time was 5 min. Intra- and inter-assay precision expressed as coefficient of variation were better than 9.1% with more than 96% recovery. The method was applied retrospectively and prospectively for the diagnosis of hepatorenal tyrosinemia and for follow-up of patients under treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16384749     DOI: 10.1016/j.jchromb.2005.12.010

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

1.  Hereditary tyrosinemia type 1 from a single center in Egypt: clinical study of 22 cases.

Authors:  Hanaa El-Karaksy; Mona Fahmy; Mona El-Raziky; Nehal El-Koofy; Rokaya El-Sayed; Mohamed S Rashed; Hasan El-Kiki; Ahmad El-Hennawy; Nabil Mohsen
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

2.  Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry.

Authors:  James J Pitt
Journal:  Clin Biochem Rev       Date:  2009-02

3.  Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough?

Authors:  Hanaa El-Karaksy; Mohmmad Rashed; Rokaya El-Sayed; Mona El-Raziky; Nehal El-Koofy; Manal El-Hawary; Osama Al-Dirbashi
Journal:  Eur J Pediatr       Date:  2009-10-31       Impact factor: 3.183

4.  Clinical experience with hepatorenal tyrosinemia from a single Egyptian center.

Authors:  Hanaa El-Karaksy; Hala Mohsen Abdullatif; Carolyne Morcos Ghobrial; Engy Adel Mogahed; Noha Adel Yasin; Noha Talal; Mohamed Rashed
Journal:  PLoS One       Date:  2022-05-10       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.